Implanon: A new contraceptive implant

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 37, Issue 3, 2008, Pages 361-368

  Fischer, Mary A ^a,b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Contraception; Contraceptive implants; Etonogestrel; Progestin only contraception

Indexed keywords

EID: 44649149584     PISSN: 08842175     EISSN: 15526909     Source Type: Journal    
DOI: 10.1111/j.1552-6909.2008.00247.x     Document Type: Article

References (41)

1. Affandi, B. (1998). An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®. Contraception, 58(6 Suppl.), 99S-107S.
2. Affandi, B. (2002). Long-acting progestogens. Best Practice & Research in Clinical Obstetrics & Gynaecology, 16, 169-179.
3. Beerthuizen, R., van Beek, A., Massai, R., Makarainen, L., Hout, J., & Bennink, H. C. (2000). Bone mineral density during long-term use of the progestagen contraceptive implant Implanon® compared to a non-hormonal method of contraception. Human Reproduction, 15, 118-122.
4. Bennink, H. J. (1998). Presentation of clinical data on Implanon®. Contraception, 58, 75S-77S.
5. Bensouda-Grimaldi, L., Jonville-Bera, A. P., Beau-Salinas, F., Llabres, S., Autret-Leca, E.; Le Reseau Des Centres Regionaux De,Pharmacovigilance. (2005). [Insertion problems, removal problems, and contraception failures with implanon]. Gynecologie, Obstetrique & Fertilite, 33, 986-990.
6. Bitzer, J., Tschudin, S., Alder, J., & Swiss Implanon Study Group. (2004). Acceptability and side-effects of Implanon® in Switzerland: A retrospective study by the Implanon® Swiss Study Group. European Journal of Contraception & Reproductive Health Care, 9, 278-284.
7. Brache, V., Faundes, A., & Alvarez, F. (2003). Risk-benefit effects of implantable contraceptives in women. Expert Opinion on Drug Safety, 2, 321-332.
8. Brache, V., Faundes, A., Alvarez, F., & Cochon, L. (2002). Nonmenstrual adverse events during use of implantable contraceptives for women: Data from clinical trials. Contraception, 65, 63-74.
9. Croxatto, H. B., & Makarainen, L. (1998). The pharmacodynamics and efficacy of Implanon®. An overview of the data. Contraception, 58 (6 Suppl.), 91S-97S.
10. Croxatto, H. B., Urbancsek, J., Massai, R., Coelingh Bennick, H., & van Beek, A. (1999). A multicentre efficacy and safety study of the single contraceptive implant Implanon®. Human Reproduction, 14, 976-981.
11. Davies, G. C., Feng, L. X., Newton, J. R., Van Beek, A., & Coelingh Bennick, H. J. (1993). Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception, 47, 251-261.
12. Dorflinger, L. J. (2002). Metabolic effects of implantable steroid contraceptives for women. Contraception, 65, 47-62.
13. Elton, J. (2006). The Implanon implant. Practice Nurse, 31, 44, 46-48, 50.
14. Flores, J. B., Balderas, M. L., Bonilla, M. C., & Vazquez-Estrada, L. (2005). Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. International Journal of Gynaecology & Obstetrics, 90, 228-233.
15. Funk, S., Miller, M. M., Mishell, D. R., Archer, D. F., Poindexter, A., Schmidt, J., et al. (2005). Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel. Contraception, 71, 319-326.
16. Gaffield, M. E., Curtis, K. M., Mohllajee, A. P., & Peterson, H. B. (2006). Medical eligibility criteria for new contraceptive methods: Combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant. Contraception, 73, 134-144.
17. Glasier, A. (2002). Implantable contraceptives for women: Effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception, 65, 29-37.
18. Harrison-Woolrych, M., & Hill, R. (2005). Unintended pregnancies with the etonogestrel implant (implanon): A case series from postmarketing experience in Australia. Contraception, 71, 306-308.
19. Huber, J. (1998). Pharmacokinetics of Implanon®. An integrated analysis. Contraception, 58(6 Suppl.), 85S-90S.
20. Implanon. (2006). Physician Insert. Roseland, NJ: Organon USA.
21. Implanon. (2007). About Implanon™ (media section). Retrieved February 4, 2008, from http://www.implanon-usa.com/consumer/ whatisimplanon/index.asp?C=62664394851253356481&svarqvp2=0
22. Lakha, F., & Glasier, A. F. (2006). Continuation rates of Implanon® in the UK: Data from an observational study in a clinical setting. Contraception, 74, 287-289.
23. Le, J., & Tsourounis, C. (2001). Implanon: A critical review. Annals of Pharmacotherapy, 35, 329-336.
24. Mascarenhas, L. (1998). Insertion and removal of Implanon®. Contraception, 58 (6 Suppl.), 79S-83S.
25. Mascarenhas, L., van Beek, A., Coelingh-Bennick, H., & Newton, J. (1998). A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Human Reproduction, 13, 3057-3060.
26. Meirik, O., Fraser, I. S., d'Arcangues, C.; for the WHO Consultation on Implantable Contraceptives for Women. (2003). Implantable contraceptives for women. Human Reproduction Update, 9, 49-59.
27. A new progestin implant (Implanon™) for long-term contraception. Medical Letter on Drugs and Therapeutics, 48, 83-84.
28. Ogbonmwan, S., Briggs, P., & Amu, O. (2006). The oestrogen 'sparing' effect of Implanon: A case report and review. European Journal of Contraception & Reproductive Health Care, 11, 109 - -111.
29. Power, J., French, R., & Cowan, F. (2007). Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database of Systematic Reviews, 3.
30. Rai, K., Gupta, S., & Cotter, S. (2004). Experience with Implanon in a northeast London family planning clinic. European Journal of Contraception & Reproductive Health Care, 9, 39-46.
31. Reinprayoon, D., Taneepanichskul, S., Bunyavejchevin, S., Thaithumyanon, P., Punnahitananda, S., Tosukhowong, P., et al. (2000). Effects of the etonogestrel-releasing contraceptive implant Implanon® on parameters of breastfeeding compared to those of an intrauterine device. Contraception, 62, 239-246.
32. Sergent, F., Clamageran, C., Bastard, A. M., Verspyck, E., & Marpeau, L. (2004). [Acceptability of the etonogestrel-containing contraceptive implant (Implanon)]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 33, 407-415.
33. Shulman, L. P., & Gabriel, H. (2006). Management and localization strategies for the nonpalpable Implanon rod. Contraception, 73, 325-330.
34. Speroff, L., & Darney, P. D. (2005). A clinical guide for contraception (4th ed.). Philadelphia: Lippincott Williams & Wilkins.
35. Taneepanichskul, S., Reinprayoon, D., Thaithumyanon, P., Praisuwanna, P., Tosukhowong, P., & Dieben, T. (2006). Effects of the etonogestrel-releasing implant Implanon® and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception, 73, 368-371.
36. Urbancsek, J. (1998). An integrated analysis of nonmenstrual adverse events with Implanon®. Contraception, 58(6 Suppl.), 109S-115S.
37. Van den Bosch, T., Donders, G. G., Riphagen, I., Debois, P., Ameye, L., De Brabanter, J., et al. (2002). Ultrasonographic features of the endometrium and the ovaries in women on etonogestrel implant. Ultrasound in Obstetrics & Gynecology, 20, 377-380.
38. Vidin, E., Garbin, O., Rodriguez, B., Favre, R., & Bettahar-Lebugle, K. (2007). Removal of etonogestrel contraceptive implants in the operating theater: Report on 28 cases. Contraception, 76, 35-39.
39. Wechselberger, G., Wolfram, D., Pulzl, P., Soelder, E., & Schoeller, T. (2006). Nerve injury caused by removal of an implantable hormonal contraceptive. American Journal of Obstetrics & Gynecology, 195, 323-326.
40. Weisberg, E., & Fraser, I. (2005). Australian women's experience with Implanon. Australian Family Physician, 34, 694-696.
41. Wenck, B. C., & Johnston, P. J. (2004). Implanon and medical indemnity: A case study of risk management using the Australian standard. Medical Journal of Australia, 181, 117-119.